It seems that experts were right, after all. COVID-19 mortality can be reduced with the help of this specific substance. Check out the latest reports below.
This is the medicine that can reduce COVID-19 mortality
A recent study has shown that individuals who received hydroxychloroquine with another drug while being hospitalized with COVID-19 had a lower likelihood of mortality compared to those who did not receive the drug. Hydroxychloroquine, which is commonly used to treat malaria and arthritis, was administered to hundreds of COVID-19 patients in Belgium while thousands of others did not receive the medication.
The study analyzed the medical records of 352 adults admitted to AZ Groeninge Hospital in Kortrijk, Belgium, who either tested positive for COVID-19 or showed signs of the disease on CT scans. Patients received either hydroxychloroquine by itself or in combination with azithromycin, an antibiotic. Before and after treatment, patients underwent CT scans.
A group of researchers conducted a study to compare the effectiveness of hydroxychloroquine treatment for COVID-19 patients with a control group that received standard care.
The control group consisted of 3,533 patients hospitalized across Belgium from March 14, 2020, to May 24, 2020, who did not receive hydroxychloroquine.
After 28 days of diagnosis, it was found that 16.7% of the patients who received hydroxychloroquine had died, which was lower than the 25.9% mortality rate in the control group.
The researchers also discovered that patients who received hydroxychloroquine were more likely to survive even after considering age and other factors.
“Our study suggests that, despite the controversy surrounding its use, treatment with hydroxychloroquine and azithromycin remains a viable option,” Dr. Gert Meeus, a nephrologist with AZ Groeninge Hospital, and other researchers wrote.
A research paper about the effectiveness of hydroxychloroquine against COVID-19 was published in the journal New Microbes and New Infections. It’s important to note that the study was retrospective in nature, and there were differences between the treatment and control groups.
The former group was, on average, younger than the latter. The authors of the study declared no conflicts of interest or funding.
The findings of this research add to a mixed dataset on the effectiveness of hydroxychloroquine against COVID-19. While some studies have shown that hydroxychloroquine recipients were less likely to die, including one conducted in Michigan, which analyzed records from a health system, most of the positive findings concerned hydroxychloroquine when used in combination with azithromycin.
However, other studies have found little or no evidence to support the use of hydroxychloroquine against COVID-19. For instance, a U.S. government-funded study across 34 hospitals did not find any significant effects of the drug.
Several studies on the use of hydroxychloroquine for the treatment of COVID-19 have been withdrawn.
Although hydroxychloroquine is an FDA-approved drug, the agency has cautioned against its use for COVID-19 since mid-2020. In June 2020, Belgian regulators revoked the authorization for the use of hydroxychloroquine for COVID-19 treatment.